Johnson & Johnson vs Post Holdings: Revenue, Profit and Business Model
Johnson & Johnson reported $94.2B of revenue in FY2025 and $26.8B of net income. Post Holdings reported $6.2B of revenue in FY2026 and $242.1M of net income.
Latest financial snapshot
Johnson & Johnson
- Latest revenue
- $94.2B (FY2025)
- Net income
- $26.8B
- Net margin
- 28.5%
- Revenue growth
- +3.0% a year, FY2016–FY2025
Post Holdings
- Latest revenue
- $6.2B (FY2026)
- Net income
- $242.1M
- Net margin
- 3.9%
- Revenue growth
- +2.1% a year, FY2016–FY2026
Financial summary
Johnson & Johnson
J&J's sales grew from $85.2 billion in 2023 to $88.8 billion in 2024 and $94.2 billion in 2025, while FY2025 net earnings reached $26.8 billion. Q2 2026 sales were $25.31 billion (Innovative Medicine $16.38 billion, MedTech $8.93 billion), net earnings were $5.53 billion, adjusted EPS was $2.90, and first-half free cash flow was about $8.7 billion. Management guides 2026 sales of $100.8 to $101.4 billion and adjusted EPS of $11.60 to $11.75. The company has raised its dividend for more than 60 consecutive years, and its market value was roughly $644 billion in mid-September 2026.
Post Holdings
Post Holdings grew net sales from $4.71 billion in fiscal 2020 to $8.158 billion in fiscal 2025, mostly through acquisitions such as the Smucker pet food brands (2023), Perfection Pet Foods (2023), Potato Products of Idaho (March 2025) and 8th Avenue Food & Provisions (July 2025). Fiscal 2025 net earnings were $335.7 million. For the nine months to June 30, 2026, net sales rose to $6.166 billion and Adjusted EBITDA to $1.191 billion, while net earnings fell 15% to $242.1 million on higher interest costs. Post does not pay a dividend and repurchased 9.1 million shares for $908.8 million in the first nine months of fiscal 2026. Management narrowed fiscal 2026 Adjusted EBITDA guidance to $1.56-$1.57 billion.
Revenue and profit by year
Johnson & Johnson
| Year | Revenue | Net income | Margin | Growth | Source |
|---|---|---|---|---|---|
| FY2025 | $94.2B | $26.8B | 28.5% | +6.0% | Source |
| FY2024 | $88.8B | $14.1B | 15.8% | +4.3% | Source |
| FY2023 | $85.2B | $35.2B | 41.3% | +6.5% | Source |
| FY2022 | $80B | $17.9B | 22.4% | +1.6% | Source |
| FY2021 | $78.7B | $20.9B | 26.5% | -4.7% | Source |
| FY2020 | $82.6B | $14.7B | 17.8% | +0.6% | Source |
| FY2019 | $82.1B | $15.1B | 18.4% | +0.6% | Source |
| FY2018 | $81.6B | $15.3B | 18.8% | +6.7% | Source |
| FY2017 | $76.5B | $1.3B | 1.7% | +6.3% | Source |
| FY2016 | $71.9B | $16.5B | 23.0% | — | Source |
Post Holdings
| Year | Revenue | Net income | Margin | Growth | Source |
|---|---|---|---|---|---|
| FY2026 | $6.2B | $242.1M | 3.9% | -24.4% | Source |
| FY2025 | $8.2B | $335.7M | 4.1% | +3.0% | Source |
| FY2024 | $7.9B | $366.7M | 4.6% | +13.3% | Source |
| FY2023 | $7B | $301.3M | 4.3% | +19.5% | Source |
| FY2022 | $5.9B | $756.6M | 12.9% | +17.5% | Source |
| FY2021 | $5B | $166.7M | 3.3% | +5.7% | Source |
| FY2020 | $4.7B | $800,000 | 0.0% | -17.1% | Source |
| FY2019 | $5.7B | $124.7M | 2.2% | -9.2% | Source |
| FY2018 | $6.3B | $467.3M | 7.5% | +19.7% | Source |
| FY2017 | $5.2B | $48.3M | 0.9% | +4.0% | Source |
| FY2016 | $5B | -$3.3M | -0.1% | — | Source |
Where the revenue comes from
Johnson & Johnson
- Innovative Medicine~64%
Innovative Medicine generated $60.401 billion in FY2025 sales across oncology, immunology, neuroscience, pulmonary hypertension, infectious disease, and cardiovascular/metabolism.
- MedTech~36%
MedTech generated $33.792 billion in FY2025 sales across surgery, orthopaedics, cardiovascular, and vision products.
Post Holdings
- Post Consumer Brands
Not formally reported
Cereal, granola, pet food, nut butters, and pantry products.
- Weetabix
Not formally reported
U.K. cereal and breakfast products.
- Foodservice
Not formally reported
Egg products and foodservice ingredients.
- Refrigerated Retail
Not formally reported
Bob Evans side dishes, sausage and egg products. The Crystal Farms dairy business was sold on May 1, 2026.
Business model and strategy
Johnson & Johnson
How it makes money
J&J makes money in two ways. Innovative Medicine (about 64% of FY2025 sales, $60.4 billion) sells patented prescription medicines to wholesalers, specialty pharmacies, hospitals, and governments; key products include DARZALEX for multiple myeloma, TREMFYA and STELARA in immunology, ERLEADA in prostate cancer, CARVYKTI cell therapy, and CAPLYTA, added through the 2025 Intra-Cellular Therapies deal.
Growth strategy
J&J is narrowing its portfolio toward higher-growth areas. It spun off consumer health as Kenvue in 2023, announced in October 2025 that it will separate its orthopaedics business as DePuy Synthes, and used acquisitions to refill its pipeline: Abiomed ($16.6 billion, 2022), Shockwave Medical ($13.1 billion, 2024), and Intra-Cellular Therapies ($14.6 billion, 2025).
Competitive advantage
J&J's edge is breadth plus balance-sheet strength. It runs one of the largest pharmaceutical R&D budgets in the industry, holds a AAA credit rating from S&P (one of only two US companies with that rating, alongside Microsoft), and sells into hospitals across pharmaceuticals and devices at the same time.
Post Holdings
How it makes money
Post makes money by manufacturing and selling packaged food through four segments. Post Consumer Brands sells branded and private-label cereal and granola (Honey Bunches of Oats, Pebbles, Malt-O-Meal), pet food (Rachael Ray Nutrish, Nature's Recipe, 9Lives, Kibbles 'n Bits) and Peter Pan peanut butter to grocery, mass and club retailers.
Growth strategy
Post grows mainly by buying businesses and integrating them into existing plants and sales teams. Recent moves include the $1.2 billion purchase of Smucker pet food brands (April 2023), Perfection Pet Foods for $235 million (December 2023), Potato Products of Idaho (March 2025) and 8th Avenue Food & Provisions (July 2025).
Competitive advantage
Post's edge is scale in less glamorous categories plus a capital-allocation discipline that treats acquisitions, debt and buybacks as interchangeable uses of cash. Michael Foods is a major supplier of value-added eggs to foodservice, Weetabix is the UK's number-one selling ready-to-eat cereal brand, and Post Consumer Brands covers both branded and private-label cereal, which lets it sell to shoppers who trade down.
Questions about Johnson & Johnson vs Post Holdings
Which company has higher revenue — Johnson & Johnson or Post Holdings, Inc.?
Johnson & Johnson reported $94.2B (FY2025), while Post Holdings, Inc. reported $6.2B (FY2026). By last reported revenue, Johnson & Johnson is the larger business, with Post Holdings, Inc. reporting a smaller revenue base. Note: these are from different fiscal years and are not a direct like-for-like comparison.
What is the market cap of Johnson & Johnson vs Post Holdings, Inc.?
Johnson & Johnson's market capitalisation stands at $643.9B, while Post Holdings, Inc.'s is $4.7B. Johnson & Johnson carries the higher market valuation, reflecting investors' expectations of its future earnings power relative to Post Holdings, Inc..
Which is more financially efficient — Johnson & Johnson or Post Holdings, Inc.?
Johnson & Johnson generates $669k / employee in revenue per employee, while Post Holdings, Inc. generates $468k / employee. Johnson & Johnson shows higher revenue efficiency per headcount, though this reflects business model differences — capital-light software companies routinely outperform labour-intensive manufacturers on this metric.
How do Johnson & Johnson and Post Holdings, Inc. make money?
Johnson & Johnson and Post Holdings, Inc. generate revenue in fundamentally different ways. Johnson & Johnson: J&J makes money in two ways. Post Holdings, Inc.: Post makes money by manufacturing and selling packaged food through four segments.
Which company is valued higher relative to revenue — Johnson & Johnson or Post Holdings, Inc.?
On a price-to-sales (P/S) basis, Johnson & Johnson trades at 6.8x P/S and Post Holdings, Inc. at 0.8x P/S. Johnson & Johnson commands a higher revenue multiple, typically indicating that investors expect faster growth or higher future margins compared to Post Holdings, Inc.. A higher multiple is not inherently better — it may also signal that the stock is priced for perfection.
Is Johnson & Johnson bigger than Post Holdings, Inc.?
By last reported revenue, Johnson & Johnson ($94.2B (FY2025)) is the larger company compared to Post Holdings, Inc. ($6.2B (FY2026)). Revenue scale is one dimension of size — market capitalisation, employee count, and geographic reach are also relevant depending on the context.
Figures come from each company's filings and the sources linked beside them. Amounts reported in another currency are shown in US dollars at an approximate rate and marked with ~. Back to the Johnson & Johnson vs Post Holdings overview